MacroGenics Inc. (MGNX)’s Financial Results Comparing With Allena Pharmaceuticals Inc. (NASDAQ:ALNA)

MacroGenics Inc. (NASDAQ:MGNX) and Allena Pharmaceuticals Inc. (NASDAQ:ALNA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MacroGenics Inc. 65.09M 11.41 166.93M -3.87 0.00
Allena Pharmaceuticals Inc. N/A 0.00 39.19M -1.89 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents MacroGenics Inc. (NASDAQ:MGNX) and Allena Pharmaceuticals Inc. (NASDAQ:ALNA)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
MacroGenics Inc. -256.46% -57.7% -44.8%
Allena Pharmaceuticals Inc. 0.00% -73.3% -57.3%

Liquidity

MacroGenics Inc.’s Current Ratio and Quick Ratio are 6.5 and 6.5 respectively. The Current Ratio and Quick Ratio of its competitor Allena Pharmaceuticals Inc. are 7.8 and 7.8 respectively. Allena Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to MacroGenics Inc.

Analyst Recommendations

MacroGenics Inc. and Allena Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MacroGenics Inc. 1 2 3 2.50
Allena Pharmaceuticals Inc. 0 0 0 0.00

MacroGenics Inc.’s upside potential is 65.90% at a $25.25 consensus target price.

Institutional and Insider Ownership

The shares of both MacroGenics Inc. and Allena Pharmaceuticals Inc. are owned by institutional investors at 78.9% and 88.3% respectively. Insiders owned roughly 0.8% of MacroGenics Inc.’s shares. Insiders Comparatively, owned 8.27% of Allena Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MacroGenics Inc. -7.29% -6.98% -23.58% -6.28% -24.64% 28.11%
Allena Pharmaceuticals Inc. -5.13% -5.91% -10.33% -29.35% -64.63% 5.14%

For the past year MacroGenics Inc.’s stock price has bigger growth than Allena Pharmaceuticals Inc.

Summary

MacroGenics Inc. beats Allena Pharmaceuticals Inc. on 6 of the 10 factors.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companyÂ’s products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The companyÂ’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.